Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36-week, phase 2 study
In this medfyle
In people with T2D, retatrutide demonstrated clinically meaningful improvements in glycaemic control and robust clinically meaningful body weight loss compared to placebo and dulaglutide, with a safety profile consistent with GLP-1 receptor agonist and GIP/GLP-1 receptor agonist classes.
Expert commentary
About this Medfyle
This is a summary of a presentation given at the EASD 2023 Annual Meeting. The content is developed by Infomedica in collaboration with the Diabetes Education Study Group (DESG).
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the DESG.
©2023 Infomedica-Medfyle. All rights reserved.
